Tower Research Capital (TRC)’s Arcus Biosciences RCUS Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $226K | Sell |
7,328
-6,649
| -48% | -$164K | 0.01% | 1596 |
|
|
2026
Q1 | $302K | Buy |
13,977
+9,152
| +190% | +$198K | 0.01% | 1295 |
|
|
2025
Q4 | $115K | Sell |
4,825
-2,224
| -32% | -$45.4K | ﹤0.01% | 1847 |
|
|
2025
Q3 | $95.9K | Sell |
7,049
-1,400
| -17% | -$14.6K | ﹤0.01% | 2023 |
|
|
2025
Q2 | $68.8K | Buy |
8,449
+5,476
| +184% | +$46.8K | ﹤0.01% | 2702 |
|
|
2025
Q1 | $23.3K | Sell |
2,973
-4,210
| -59% | -$48.8K | ﹤0.01% | 2820 |
|
|
2024
Q4 | $107K | Buy |
7,183
+456
| +7% | +$7.45K | ﹤0.01% | 2115 |
|
|
2024
Q3 | $103K | Sell |
6,727
-11,788
| -64% | -$186K | ﹤0.01% | 2213 |
|
|
2024
Q2 | $282K | Buy |
18,515
+17,928
| +3,054% | +$289K | ﹤0.01% | 1818 |
|
|
2024
Q1 | $11.1K | Sell |
587
-1,927
| -77% | -$33.3K | ﹤0.01% | 3605 |
|
|
2023
Q4 | $48K | Sell |
2,514
-2,270
| -47% | -$36.3K | ﹤0.01% | 3158 |
|
|
2023
Q3 | $85.9K | Sell |
4,784
-2,594
| -35% | -$52.1K | ﹤0.01% | 2092 |
|
|
2023
Q2 | $150K | Buy |
7,378
+3,490
| +90% | +$66.5K | 0.01% | 1755 |
|
|
2023
Q1 | $71K | Sell |
3,888
-3,246
| -46% | -$62K | ﹤0.01% | 2189 |
|
|
2022
Q4 | $147K | Buy |
7,134
+2,710
| +61% | +$74.6K | 0.01% | 1531 |
|
|
2022
Q3 | $115K | Sell |
4,424
-8,550
| -66% | -$226K | ﹤0.01% | 2449 |
|
|
2022
Q2 | $329K | Buy |
12,974
+10,428
| +410% | +$255K | 0.01% | 1416 |
|
|
2022
Q1 | $81K | Sell |
2,546
-2,050
| -45% | -$68.7K | ﹤0.01% | 2369 |
|
|
2021
Q4 | $186K | Sell |
4,596
-2,955
| -39% | -$115K | ﹤0.01% | 1828 |
|
|
2021
Q3 | $263K | Buy |
7,551
+2,922
| +63% | +$90.9K | 0.01% | 1553 |
|
|
2021
Q2 | $128K | Sell |
4,629
-46
| -1% | -$1.31K | ﹤0.01% | 2223 |
|
|
2021
Q1 | $131K | Buy |
4,675
+2,699
| +137% | +$93.9K | ﹤0.01% | 2360 |
|
|
2020
Q4 | $51K | Sell |
1,976
-4,992
| -72% | -$121K | ﹤0.01% | 3107 |
|
|
2020
Q3 | $119K | Sell |
6,968
-13,651
| -66% | -$305K | ﹤0.01% | 3016 |
|
|
2020
Q2 | $510K | Buy |
+20,619
| New | +$556K | 0.02% | 1017 |
|
|
2019
Q4 | – | Sell |
-1,052
| Closed | -$10K | – | 4223 |
|
|
2019
Q3 | $10K | Buy |
+1,052
| New | +$8.45K | ﹤0.01% | 2940 |
|
|
2019
Q2 | – | Sell |
-4,870
| Closed | -$61K | – | 4169 |
|
|
2019
Q1 | $61K | Buy |
+4,870
| New | +$52.9K | ﹤0.01% | 1675 |
|
|
2018
Q4 | – | Sell |
-56
| Closed | -$1K | – | 4260 |
|
|
2018
Q3 | $1K | Sell |
56
-2,160
| -97% | -$27.5K | ﹤0.01% | 3611 |
|
|
2018
Q2 | $27K | Buy |
+2,216
| New | +$34.8K | ﹤0.01% | 2242 |
|
Other funds holding RCUS
GS
SCM
WP
Tower Research Capital (TRC)'s RCUS Position: Q2 2026 in Review
Tower Research Capital (TRC) reduced its Arcus Biosciences (RCUS) stake by 48% in Q2 2026, selling an estimated $164K and leaving 7,328 shares worth $226K. The position accounts for 0.01% of the portfolio, ranked #1596.
Tower Research Capital (TRC) first reported a position in RCUS in Q2 2018 and has held it in 29 quarters since. The position peaked at $510K in Q2 2020. 231 funds tracked by Wall St. Rank hold RCUS as of Q2 2026.
- Tower Research Capital (TRC) held 7,328 shares of Arcus Biosciences worth $226K as of Q2 2026.
- Tower Research Capital (TRC) sold 6,649 Arcus Biosciences shares in Q2 2026, an estimated $164K.
- Arcus Biosciences made up 0.01% of Tower Research Capital (TRC)'s portfolio in Q2 2026, its #1596 holding.
- Tower Research Capital (TRC) first reported a position in Arcus Biosciences in Q2 2018 and has held it in 29 quarters since.
- Tower Research Capital (TRC)'s Arcus Biosciences position peaked at $510K in Q2 2020.
- 231 funds tracked by Wall St. Rank held Arcus Biosciences as of Q2 2026.
Based on Tower Research Capital (TRC)'s 13F filing for Q2 2026, filed 11 Aug 2026.